News
Opdivo plus Yervoy combo approved in EU for first-line lung cancer
Bristol Myers Squibb’s Opdivo (nivolumab) plus Yervoy (ipilimumab) has received approval from the European Commission for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC).